FDA
-
-
-
-
-
-
-
BTIG Reiterates Neutral Rating on Tscan Therapeutics Inc (TCRX)
-
-
-
-
-
-
-
TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027
-
-
-
-
-
-
-
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
-
-
-
-
-
-
-
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones
-
-
-
-
-
-
-
TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
-
-
-
-
-
-
-
TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones
-
329,910 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

